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A recent study by Karunakaran et al. has suggested RIPK1 is important in obesity and related metabolic 10 
traits. With genetic variation associated with expression and the risk of obesity, and repression of activity 11 
leading to a favorable metabolic profile in an obesogenic model, is there evidence for a potential 12 
therapeutic role?  13 
 14 
Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is a regulator of autoinflammatory 15 
systems and appears intimately involved in the coordination of events around cell death. There is a body 16 
of evidence which marks out RIPK1 as an important regulator for inflammatory events in both normative 17 
settings and disease. RIPK1 is able to play a role in the triggering of cell death, but it also can act to 18 
regulate inflammatory signaling and promote cell survival1. Indeed, in atherosclerosis, it has been 19 
suggested that pathways involved in necrosis are triggered and that this can predispose weakness in 20 
plaques/lesions2. This flags such regulators for therapeutic interventions and RIPK1 has received recent 21 
attention. RIPK1 is not only a potential route to the modulation of key biological systems important in 22 
common complex disease1, but it is also an exciting and tractable target2. This is the because of the 23 
kinase structure of RIPK1 being an excellent target for the development of potentially effective specific 24 
pharmacological small-molecule inhibitors.  25 
 26 
The present work (*ref) suggests that genetic variation at the RIPK1 locus (or nearby) is associated with 27 
expression of the coded protein and that these events are also associated with the risk of obesity in 28 
human. Whilst the finding of an association between cis variation and expression is not entirely 29 
surprising, the authors are also able to show that one of the associated single nucleotide polymorphisms 30 
is within a transcription factor binding site associated with promoter activity and RIPK1 gene expression 31 
in adipose. This is then further advanced by the observed effects of therapeutic silencing in a model of 32 
diet induced obesity - associated with fat mass, total body weight, improved insulin sensitivity, reduced 33 
macrophage count and promoted invariant natural killer T-cell accumulation. These events, which are of 34 
course subject to the limitations of system level interpretation are fascinating and more-so flag the 35 
importance of multi-pronged assessment of likely biological function. This type of evidence triangulation 36 
has been promoted in other fields3,4 and is the hallmark of exceptional science looking to start breaking 37 
down biological complexities into real understanding. In this new work on RIPK1, there is a refreshing 38 
combination of human genetic epidemiology, model and cell work which builds on the story of this gene 39 
and the potential role it has in a range of important biological processes (Figure 1).  40 
 41 
More generally, this paper forms part of a growing collection of studies looking to use genetic variation to 42 
increase the functional understanding of underlying biological events. It is increasingly clear that there is 43 
breadth in the shape of genetic contributions to disease5 and whilst the associations with outcomes and 44 
intermediate traits are reliable, the architecture of these genetic contributions varies wildly. That said, it is 45 
clear that the differing types of genetic association study are useful and capable of yielding insight into 46 
pathways of interest. What is less clear, however, is how one navigates the difficult path of moving from 47 
signal to biological understanding.  48 
 49 
This tricky road has been walked by papers which really have started to use sensible collections of 50 
existing resources to unpick the deeper stories behind association results. For example, the strong 51 
association between genetic variation at FTO on chromosome 16 and adiposity uncovered in part 52 
through its logical relationship with type 2 diabetes6,7 has been well cross-examined and by those able to 53 
deploy existing collections of deep genomic data to explore why and how the association might exist8. 54 
Indeed, some of the earliest association signals for adiposity coming first from familial studies of extreme 55 
phenotype are now being explored with both a view to the existence of common and well explored rare 56 
genetic variation9. Despite these advances, the bridge between reliable signal and function – which 57 
theoretically can lead to an ability to consider possible therapeutic value – is one which remains 58 
extremely difficult to cross, but is the paradigm of the work discussed here.  59 
 60 
Finding genetic variation at, or around RIPK1 (some of which looks to be regulatory) which is associated 61 
with expression in the appropriate tissue and which is associated with a risk of elevated adiposity is 62 
compelling. The combination of this with analysis of therapeutically knocked down expression in an 63 
overweight model and the observation of the right “milieu” of biological events (inflammatory, 64 
immunological, body composition and glycemic profile) is exciting and brings a clear addition to an 65 
existing literature. However, one is constantly reminded that there are rarely enough tools to fully assess 66 
a complex regulatory network such as that involving RIPK1. The suppression of a key regulator seems 67 
likely to inevitably yield systemic changes and the qualification of specific genetic variants as useful 68 
proxies/handles for understanding the impact of RIPK1 on obesity leaves a cautionary feel to the new 69 
work. Furthermore, with inflammation and body composition in particular, one enters the murky waters of 70 
reverse causation and likely bidirectional effects, which would require careful examination before 71 
embarking on work setting out to measure clinical effectiveness. 72 
 73 
This work clearly has not refuted the likely importance of RIPK1 and at worst has marked it as a sentinel 74 
or reporter for a network of regulatory events which are coincident in a number of complex diseases. 75 
Evidence presented by Karunakaran and colleagues furthers the hypothesis that there is likely to be a 76 
meaningful biological read out of specific therapeutic manipulation of RIPK1 (even if subject to the 77 
complexities and redundancies of the systems targeted). Furthermore, the work has delivered a multi-78 
pronged attack on trying to understand the potential role of RIPK1 across cell, model and human 79 
investigation. There is potential in this attractive target to deliver increased metabolic control in the 80 
context of a prevailing obesogenic environment and population level obesity control aside, this parallel 81 
development is a tantalizing prospect. 82 
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Figure 1. Triangulation of evidence around RIPK1 as a candidate for a role in body composition related 135 




Schematic representing multiple independent sources of evidence highlighting the likely importance of RIPK1. A – human 140 
studies relating genetic variation at RIPK1 associated with expression, risk of obesity and suggesting a causal role for RIPK1 in 141 
adiposity, B – murine studies suggesting that the specific repression of RIPK1 expression affects a suite of metabolic traits in a 142 
diet induced model of obesity. C – evidence that genetic variation relating to human studies resides in a transcription factor 143 
binding site for E4BP4 and influences RIPK1 promotion. Green arrows indicate evidence from Karunakaran et al. and from 144 
different sources supporting important roles for RIPK1 in obesity and metabolic traits. Red arrows are indicative of important 145 
followup work which can be prompted by that reported by Karunakaran et al. ASO refers to Anti-sense oligonucleotide, MR 146 
refers to Mendelian randomisation and eQTL refers to expression quantitative trait locus. METSIM1 gives reference to Metabolic 147 
Syndrome in Men Study which was used to examine the relationship between genetic variation at RIPK1 andRIPK1 mRNA 148 
(eQTL discovery)10. OTTAWA2 refers to a cohort of participants recruited for the study of genetic variation at the FTO locus, but 149 
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